ClinicalTrials.gg
CompletedNCT03585647GeSTAUpdated Apr 17, 2019

Anesthetic Methods and Gene Expression Profile

An observational study in Hip Arthroplasty, sponsored by University of Bologna. Completed at 1 site in Italy. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2019-04-17.

Sponsored by University of Bologna · Observational

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
99
Ages
18 Years to 80 Years
Sex
All
01

Study summary

The study will analyze differentially regulated genes involved in oxidative stress and toxicology in peripheral blood mononuclear cells (PBMCs) of patients who underwent arthroplasty under three different anesthetic methods. The investigator hypothesized that anesthesia procedures trigger toxicity, thus inducing changes in the messenger ribonucleic acid (mRNA) profile. The results may provide a more profound understanding of the molecular mechanism of anesthesia and in overcoming the adverse effects arising from their use.

Read the detailed description

By using a computer-generated randomization table, hospitalized patients undergoing elective hip arthroplasty will be randomly consecutively allocated to receive general (GA group), regional (RA group), or integrated (IA group) anesthesia. Patients with contraindication to spinal anesthesia or lumbar catheter placement, as well as obese patients, with arterial hypertension not controlled by oral medication, severe pulmonary, cardiovascular, renal, hepatic, cerebrovascular, or psychiatric diseases will be excluded from the study.

Whole blood samples (10 mL) will be obtained from all enrolled patients at three time points: early morning on the operation day (T0), after surgery (T1) and third day (T2) after surgery. The samples will be collected in heparin tubes and PBMCs will be isolated and used for gene expression analysis. Serum obtained after blood centrifugation will be used for hematological and biochemical analysis such as glutamate oxaloacetate transaminase (GOT), glutamate-pyruvate transaminase (GPT), bilirubin (BIL), creatinine (CREA), creatine phosphokinase (CPK), hemoglobin (HB).

The sample size was determined according to Lee- Whitmore * and G*Power Ftest for ANOVA Fixed effects, omnibus, one-way (Lee ML, Whitmore GA. Stat Med. 2002;21: 3543-3570). Assuming a Poisson distribution for the expected value of the false-positive gene expression of the 9 chosen genes and fixing at 1 the maximum expected value for false positives E(R0) and considering all the 84 genes as not differentially expressed (G0=G=9), the probability α for any single gene among the G genes that are not differentially expressed is given by α=E(R_0 )/G=1/9=0.011, with the Bonferroni correction it becomes α_c=(0.011)/3=0.037. This is the type I error of a false positive expression. Moreover, considering as primary endpoint the fold increase of the gene expression, assuming a log-normal distribution with standard deviation of 0.7 which is typical of moderate-high gene expression and therefore a conservative one for the sample size determination and imposing a minimum difference on logarithmic scale among the 3 groups of 0.5 with a power of at least 0.8 and a Bonferroni corrected type I error α=0.05/3=0.0167 (which is smaller and then conservative, than the previous α_c) the minimum sample size(G*POWER)\^ for each group is 30 patients, by considering a 10% of drop-out , the chosen sample size was 33 patients per group which leads to a total sample size of 99 patients.

\^F tests - ANOVA: Fixed effects, omnibus, one-way Analysis: A priori: Compute required sample size Input: Effect size f = 0.7 α err prob = 0.0167 Power (1-β err prob) = 0.8 Number of groups = 3 Output: Noncentrality parameter λ = 14.7000000 Critical F = 4.7803455 Numerator df = 2 Denominator df = 27 Total sample size = 30 Actual power = 0.8009945

The normal distribution of continuous variables will be evaluated by Kolmogorov-Smirnov test. The Chi-square test will be used to evaluate categorical variables. The differences between groups will be evaluated by means of parametric ANOVA tests followed by Tukey test. Multiple regression analysis will be performed to evaluate the influence of biochemical parameters on gene expression in response to anesthetics considering confounding factors such as age, gender, BMI, smoking. Values of p \<0.05 will be considered statistically significant. All tests will be performed using software (SPSS, Chicago, USA).

02

Conditions studied

  • Hip Arthroplasty

Keywords

  • General anesthesia
  • Regional anesthesia
  • Integrated anesthesia
  • Hip arthroplasty
  • Toxicological gene expression
03

In context

Lead sponsor

University of Bologna is the lead sponsor of 158 studies on the registry; 24 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

patients undergoing elective hip arthroplasty

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

- American Society of Anesthesiologists Classification (ASA Class) = I-II.

Exclusion criteria

Exclusion Criteria:

  • American Society of Anesthesiologists Classification (ASA Class) > III
  • contraindication to spinal anaesthesia or lumbar catheter placement
  • arterial hypertension not controlled by oral medication
  • severe pulmonary
  • cardiovascular disease
  • renal disease
  • hepatic disease
  • cerebrovascular disease
  • psychiatric diseases
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
99 participants (actual)
Patient registry
No
Biospecimen retention
Samples with dna

Groups and cohorts

  • GA-group

    Patients undergoing elective hip arthroplasty included in the GA-group received general anesthesia. GA was induced by intravenous fentanyl (1 mcg/kg) and propofol (2 mg/kg), followed by vecuronium bromide (0.1 mg/kg) to facilitate tracheal intubation, then GA was maintained using a 50% air/oxygen mixture and sevoflurane.The end-tidal concentration of sevoflurane was adjusted to maintain heart rate and blood pressure values within 20% of baseline. Mechanical ventilation was regulated to maintain the end-tidal carbon dioxide partial pressure ranging between 4.3 and 5.1 kilopascal.

    Procedure: hip arthroplasty

  • RA-group

    Patients undergoing elective hip arthroplasty included in the RA-group received regional anesthesia. Regional anaesthesia included continuous lumbar plexus block, performed by or under supervision of an experienced operator using a nerve stimulator (Stimulax, B. Braun) and Continued Peripheral Nerve Block Set. A total dose of 20 ml of 0.5% Levobupivacaine was administered at the time of catheter placement. Dural puncture was performed at the L3-L4 interspace using a 25-Gauge whitaker spinal needle (Becton-Dickinson, New Jersey, USA) with the midline approach using 3 ml of 0.5% Levobupivacaine.

    Procedure: hip arthroplasty

  • IA-group

    Patients undergoing elective hip arthroplasty included in the IA-group received integrated anesthesia. The patients received regional anaesthesia (lumbar plexus block + spinal anaesthesia) as described protocol. General anaesthesia was induced by propofol 1% and a laryngeal mask airway of appropriate size was inserted. General anaesthesia and mechanical ventilation were maintained as standard protocol.

    Procedure: hip arthroplasty

Interventions

  • Procedurehip arthroplasty

    Hip replacement is a surgery for people with severe hip damage. The most common cause of damage is osteoarthritis.

    Also known as: Hip prosthesis

06

What researchers measure

Primary outcomes

  1. Changes of Gene expression profile from baseline at time points

    Effect of anesthesia techniques on the expression of genes indicative of stress and toxicity

    Time frame: Gene expression will be evaluated in PBMCs at baseline (T0), up-30 min after surgery (T1) and on the third day (T2) after surgery.

Secondary outcomes

  1. Relationship between deregulated genes and hepatic/renal cytotoxicity from baseline at time points

    Multiple regression analysis of deregulated gene expression values (relative expression) and HB (mg/ml), hepatic markers such as GOT, GPT, BIL (mg/dl), and renal markers including CREA and CPK (mg/dl) will been performed. The results will be reported as coefficient of regression (r) with statistical significance p\<0.05.

    Time frame: Biochemical analysis have been evaluated in blood collected at baseline (T0), up-30 min after surgery (T1) and on the third day (T2) after surgery.

07

Study locations

1 site
  • Rizzoli Orthopaedic Institute
    Bologna, 40136, Italy
08

References and documents

Publications

  • Alleva R, Tomasetti M, Solenghi MD, Stagni F, Gamberini F, Bassi A, Fornasari PM, Fanelli G, Borghi B. Lymphocyte DNA damage precedes DNA repair or cell death after orthopaedic surgery under general anaesthesia. Mutagenesis. 2003 Sep;18(5):423-8. doi: 10.1093/mutage/geg013. PubMed 12960410 ↗
  • Borghi B, Casati A, Iuorio S, Celleno D, Michael M, Serafini PL, Alleva R. Effect of different anesthesia techniques on red blood cell endogenous recovery in hip arthroplasty. J Clin Anesth. 2005 Mar;17(2):96-101. doi: 10.1016/j.jclinane.2004.05.005. PubMed 15809124 ↗
  • Nakazato K, Yoshida Y, Takemori K, Kobayashi K, Sakamoto A. Expressions of genes encoding drug-metabolizing enzymes are altered after sevoflurane, isoflurane, propofol or dexmedetomidine anesthesia. Biomed Res. 2009 Feb;30(1):17-24. doi: 10.2220/biomedres.30.17. PubMed 19265259 ↗
  • Ishikawa M, Tanaka S, Arai M, Genda Y, Sakamoto A. Differences in microRNA changes of healthy rat liver between sevoflurane and propofol anesthesia. Anesthesiology. 2012 Dec;117(6):1245-52. doi: 10.1097/ALN.0b013e3182746676. PubMed 23090150 ↗
  • Alleva R, Tognu A, Tomasetti M, Benassi MS, Pazzaglia L, van Oven H, Vigano E, De Simone N, Pacini I, Giannone S, Gagic S, Borghi R, Picone S, Borghi B. Effect of different anaesthetic techniques on gene expression profiles in patients who underwent hip arthroplasty. PLoS One. 2019 Jul 25;14(7):e0219113. doi: 10.1371/journal.pone.0219113. eCollection 2019. PubMed 31344051 ↗

Individual participant data

Plan to share: No — There is not a plan to make individual patient data (IPD) available

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Sep 2014 to primary completion in Jun 2015, 9 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 14, 2018
First posted
Jul 13, 2018
StartActual
Sep 15, 2014
Primary completionActual
Jun 20, 2015
CompletionActual
Nov 30, 2016
Last update
Apr 17, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 17, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03585647
Responsible party
RAlleva (PhD, University of Bologna) — Principal investigator
First posted
Jul 13, 2018
Start date
Sep 15, 2014
Primary completion
Jun 20, 2015
Completion
Nov 30, 2016
Last update
Apr 17, 2019

Study contacts

Battista Borghi, MD
study director · Rizzoli Orthopaedic Institute

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion